, adalimumab, infliximab, certolizumab, canakinumab, tocilizumab, sarilumab, and secukinumab) are monoclonal antibodies and have special targets like tumor necrosis factor (TNF)-, interleukin (IL)-6, IL-1, and IL-17 ( Although the above mentioned DMARDs have been quite successful in mitigating RA, it is still an undeniable fact that a significant proportion of patients could experience treatment failure, including nonresponse and limited efficacy ( With the deepening of research and exploration, many molecules are identified to exert important roles and bring novel insights to prevent RA
Mathiesen DS, Bagger JI, Knop FK
No responsibility can be accepted
Researchers often choose the spray format for simplified handling in non-injection study designs
Clear knowledge improves safe medication mixing during clinical tasks
Apoptosis (30.7%), c-erbB2 expression (71.0%), and Ki-67 LI (34.2%) were all significantly reduced in the flaxseed group compared to the pre-treatment data (p = 0.001)